Results showing corneal endothelial cell regeneration with sovesudil (starting phase III clinical trial for glaucoma; also known as PHP-201) and PHP-961 was presented at the Association for Research in Vision and Ophthalmology Annual Meeting May 1st – 5th, 2022 (ARVO 2022). This study was conducted at Hallym University in collaboration...
정상안압 녹내장 2상서 '소베수딜' 안압 낮추고 부작용 개선 'best-in-class' ROCK 저해제로 개발 가능성 올해말 국내 3상 계획 및 파트너링 추진 http://www.biospectator.com/view/news_view.php?varAtcId=13929
국내 환자 많은 정상안압녹내장 환자 대상 2상, 통계적 유의성 달성 지난 5월 식약처로부터 3상 승인 받고 두 파트로 나눠 임상 준비 중 http://www.hitnews.co.kr/news/articleView.html?idxno=35435
Results testing sovesudil (PHP-201) in normal-tension glaucoma patients in a clinical study was published in the journal Acta Ophthalmologica. This study was funded by pH Pharma and was conducted at 15 clinical centres in South Korea. The study demonstrated the potential of sovesudil in providing intraocular pressure (IOP) reduction in...
Results showing neuroprotection with sovesudil (PHP-201) was presented at the World Glaucoma Congress Annual Meeting June 30th - July 3rd, 2021 (WGC 2021). This study was conducted at The University of Melbourne as a collaboration with pH Pharma. The study demonstrated the potential of sovesudil in providing neuroprotection to neurons...
Sanjeev Satyal, Head of R&D of pH PhamaImplement new technology and culture from U.S.Basic research for new drug candidate in KoreaDeveloping glaucoma and NASH treatments(For more information, please refer to the link below)https://www.hankyung.com/it/article/202003033648i
PH Pharma, an innovative new drug research and development company, recently received final approval from the UK and Ireland authorities for the Phase 2 Clinical Trial to develop PHP-303 as the treatment for alpha-1 antitrypsin deficiency.(For more information, please refer to the link below)https://www.edaily.co.kr/news/read?newsId=02745366625637392
New ADC deals between big pharma made recentlypH Pharma builds toxin library for ADC development(For more information, please refer to the link below)http://www.medigatenews.com/news/1001974809